Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 16, 2016 - Issue 7
Submit an article Journal homepage
150
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine

Frederick G. FreitagDepartment of Neurology, The Medical College of Wisconsin, Milwaukee, WI, USACorrespondence[email protected]
&
Derrick Alan ShumateDepartment of Neurology, The Medical College of Wisconsin, Milwaukee, WI, USA
Pages 743-747 | Received 18 Apr 2016, Accepted 26 May 2016, Published online: 23 Jun 2016

References

  • Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
  • Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688–695.
  • Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20.
  • Ivanusic JJ, Kwok MMK, Jennings EA. Peripheral targets of 5-HT(1D) receptor immunoreactive trigeminal ganglion neurons. Headache. 2011;51:744–751.
  • Djupesland PG, Messina JC, Mahmoud RA. Breath powered nasal delivery: a new route to rapid headache relief. Headache. 2013;53 Suppl 2:72–84.
  • Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv. 2012;25(5):280–289.
  • Obaidi M, Offman E, Messina J, et al. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. Headache. 2013;53(8):1323–1333. doi:10.1111/head.12167. Epub 2013 Aug 28.
  • Luthringer R, Djupesland PG, Sheldrake CD, et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol. 2009;61(9):1219–1228.
  • Djupesland PG, Docekal P; Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia. 2010;30(8):933–942.
  • Cady RK, McAllister PJ, Spierings ELH, et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET study). Headache. 2015;55(1):88–100.
  • Tepper SJ, Cady RK, Silberstein S, et al. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs. 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks. Headache. 2015;55(5):621–635.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.